文献速递肝病

综述:肝脏靶向治疗对非酒精性脂肪性肝炎致动脉粥样硬化风险谱的影响

Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis.
PubMed 文献 · Aliment Pharmacol Ther · 2020-07-08

该综述通过检索PubMed文献,总结NASH药物治疗对血脂和脂蛋白水平的影响及潜在机制。部分药物(如吡格列酮)对血脂有益,而法尼醇X受体激动剂等可能对循环血脂和脂蛋白产生不良影响。NASH是多系统疾病,心血管疾病负担突出,他汀类联合使用可能有助于减轻部分治疗对血脂和脂蛋白水平的负面影响。

要点

  • NASH患者心血管疾病风险及死亡率升高,需关注治疗对心血管风险因素的影响。
  • 吡格列酮对血脂有益,而法尼醇X受体激动剂等可能对血脂和脂蛋白产生不良影响。
  • 他汀类联合使用可能有助于减轻部分NASH治疗对血脂和脂蛋白水平的负面影响。

核心结论

  • NASH是多系统疾病,心血管疾病负担突出,当前和未来的NASH药物对致动脉粥样硬化风险谱影响不一。
  • 他汀类联合使用可能有助于减轻部分NASH治疗对血脂和脂蛋白水平的负面影响。

研究设计与样本

  • 综述,通过PubMed检索文献并汇总结果。

主要发现

  • 近期临床试验显示NASH候选药物具有安全性和有效性,部分药物改善NASH组织学特征和肝功能。
  • 吡格列酮(目前用于2型糖尿病,可能对NASH有用)对血脂表现出有益效应。
  • 法尼醇X受体激动剂等正在开发用于NASH的药物可能对循环血脂和脂蛋白产生不良影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with non-alcoholic fatty liver disease (NAFLD), the most common cause of chronic liver disease, are at higher risk of cardiovascular disease (CVD) and associated mortality. Therefore, it is important to understand how new therapies for non-alcoholic steatohepatitis (NASH) may impact CVD risk factors in these patients. AIMS: To summarise the effects of drug therapies on lipid and lipoprotein levels in patients with NASH and provide insight into the potential mechanisms for the observed changes. METHODS: PubMed searches of the literature were performed and results were compiled. RESULTS: Recent clinical trials have highlighted the safety and efficacy of drug candidates for the treatment of NASH. Several agents have shown improvements in the histological features of NASH and liver function. Pioglitazone, a drug that is currently available for type 2 diabetes and may be useful for NASH, exhibits beneficial effects on lipids. However, agents such as farnesoid X receptor agonists, which are in development for NASH, may adversely affect circulating lipids and lipoproteins. CONCLUSIONS: NASH is a multi-system disease with a disproportionate CVD burden. Current and future drugs for NASH have had variable impact on the atherogenic risk profile. Potential co-administration of a statin may help mitigate the negative impact of some of these therapies on lipid and lipoprotein levels.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Connelly MA, Velez Rivera J, Guyton JR, et al. Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2020. PMID: 32638417. doi:10.1111/apt.15935

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。